These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 22933863)
1. Improved understanding of risk factors could help to reduce the incidence of hepatocellular carcinoma. Tong MJ Gastroenterol Hepatol (N Y); 2012 May; 8(5):320-1. PubMed ID: 22933863 [No Abstract] [Full Text] [Related]
2. Can Statin Treatment Reduce the Risk of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis. Chang Y; Liu Q; Zhou Z; Ding Y; Yang M; Xu W; Chen K; Zhang Q; Wang Z; Li H Technol Cancer Res Treat; 2020; 19():1533033820934881. PubMed ID: 32552476 [TBL] [Abstract][Full Text] [Related]
3. Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. Wainwright P; Scorletti E; Byrne CD Curr Diab Rep; 2017 Apr; 17(4):20. PubMed ID: 28290049 [TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors of hepatocellular carcinoma after orthotopic liver transplantation. Colhoun ED; Forsberg CG; Chavin KD; Baliga PK; Taber DJ Surgery; 2017 Mar; 161(3):830-836. PubMed ID: 27771158 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis. Inoue A; Tsukuma H; Oshima A; Yabuuchi T; Nakao M; Matsunaga T; Kojima J; Tanaka S J Epidemiol; 2000 Jul; 10(4):234-40. PubMed ID: 10959605 [TBL] [Abstract][Full Text] [Related]
6. Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study. Karageorgos SA; Stratakou S; Koulentaki M; Voumvouraki A; Mantaka A; Samonakis D; Notas G; Kouroumalis EA Ann Gastroenterol; 2017; 30(3):357-363. PubMed ID: 28469367 [TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Hoffmann CJ; Subramanian AK; Cameron AM; Engels EA Transplantation; 2008 Sep; 86(6):784-90. PubMed ID: 18813102 [TBL] [Abstract][Full Text] [Related]
8. Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. Kasmari AJ; Welch A; Liu G; Leslie D; McGarrity T; Riley T Am J Med; 2017 Jun; 130(6):746.e1-746.e7. PubMed ID: 28109969 [TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. del Olmo JA; Serra MA; Rodríguez F; Escudero A; Gilabert S; Rodrigo JM J Cancer Res Clin Oncol; 1998; 124(10):560-4. PubMed ID: 9829860 [TBL] [Abstract][Full Text] [Related]
10. Development of hepatocellular carcinoma after successful management of esophageal variceal bleeding. Chen WC; Lo GH; Lai KH; Cheng JS; Hsu PI; Lin CK J Chin Med Assoc; 2004 Nov; 67(11):557-64. PubMed ID: 15720069 [TBL] [Abstract][Full Text] [Related]
11. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Dyer Z; Peltekian K; van Zanten SV Aliment Pharmacol Ther; 2005 Jul; 22(1):17-22. PubMed ID: 15963075 [TBL] [Abstract][Full Text] [Related]
12. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733 [TBL] [Abstract][Full Text] [Related]
13. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707 [TBL] [Abstract][Full Text] [Related]
14. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Shindo M; Ken A; Okuno T Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234 [TBL] [Abstract][Full Text] [Related]
15. Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis. Gao X; Yang HI; Trinh H; Jeong D; Li J; Zhang J; Le A; Hoang J; Nguyen P; Henry L; Nguyen MH Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1207-1211. PubMed ID: 32129773 [TBL] [Abstract][Full Text] [Related]
16. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Wallace MC; Preen D; Jeffrey GP; Adams LA Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):765-79. PubMed ID: 25827821 [TBL] [Abstract][Full Text] [Related]
17. Changing incidence patterns of hepatocellular carcinoma among age groups in Taiwan. Hung GY; Horng JL; Yen HJ; Lee CY; Lin LY J Hepatol; 2015 Dec; 63(6):1390-6. PubMed ID: 26256438 [TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Morgan TR Recent Results Cancer Res; 2011; 188():85-99. PubMed ID: 21253791 [TBL] [Abstract][Full Text] [Related]
19. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma. Tholey DM; Ahn J Gastroenterol Clin North Am; 2015 Dec; 44(4):761-73. PubMed ID: 26600218 [TBL] [Abstract][Full Text] [Related]
20. Increased incidence of bone metastases in hepatocellular carcinoma. Fukutomi M; Yokota M; Chuman H; Harada H; Zaitsu Y; Funakoshi A; Wakasugi H; Iguchi H Eur J Gastroenterol Hepatol; 2001 Sep; 13(9):1083-8. PubMed ID: 11564960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]